Vancomycin

• Description :

  Vancomycin is an antibiotic for the treatment of bacterial infections.

• CAS Number :

  [1404-90-6]

• UNSPSC :

  12352209

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Antibiotic; Autophagy; Bacterial

• Type :

  Natural Products

• Related Pathways :

  Anti-infection; Autophagy

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/vancomycin.html

• Concentration :

  10mM

• Purity :

  99.39

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@H]2O)([H])C[C@@]2(N)C)[C@@H](O[C@H](CO)[C@H]1O)OC3=C(OC4=CC=C([C@H]([C@H]5NC([C@H](NC)CC(C)C)=O)O)C=C4Cl)C=C([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C6=O)([H])C7=CC8=C(O)C=C7)=O)C=C3OC9=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%10=C8C(O)=CC(O)=C%10)=O)([H])N6)O)C=C9Cl

• Molecular Formula :

  C66H75Cl2N9O24

• Molecular Weight :

  1449.25

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.|[2]Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.|[3]Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57 (2) :689-96.|[4]Juan He, et al. Vitamin C reduces vancomycin-related nephrotoxicity through the inhibition of oxidative stress, apoptosis, and inflammation in mice. Ann Transl Med. 2021 Aug; 9 (16) : 1319.|[5]Ping Yu, et al. N-acetylcysteine Ameliorates Vancomycin-induced Nephrotoxicity by Inhibiting Oxidative Stress and Apoptosis in the in vivo and in vitro Models. Int J Med Sci. 2022; 19 (4) : 740–752.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Natural Products

• Clinical Information :

  Launched

• Isoform :

  Glycopeptide

• Citation 01 :

  ACS Infect Dis. 2021 Aug 13;7 (8) :2565-2582.|ACS Infect Dis. 2023 Dec 8;9 (12) :2523-2537.|ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|ACS Infect Dis. 2024 Aug 9;10 (8) :2961-2977.|ACS Infect Dis. 2025 Jun 13;11 (6) :1473-1485.|ACS Omega. 2022 Mar 3;7 (10) :9004-9014.|ACS Omega. 2023 Feb 3;8 (6) :5415-5425.|ACS Omega. 2023 Mar 6;8 (10) :9652-9661.|Adv Funct Mater. 2024 Jun 19.|Adv Sci (Weinh) . 2025 Apr 28:e2409837.|Adv Sci (Weinh) . 2025 Oct 13:e09383.|Am J Chin Med. 2024 Aug 21:1-28.|AMB Express. 2024 Dec 24;14 (1) :141.|Appl Microbiol Biotechnol. 2022 Apr;106 (7) :2689-2702.|Aquaculture. 2021, 736248.|ArXiv. 2025 Nov 7.|Basic Clin Androl. 2025 Mar 7;35 (1) :9.|Biochem Biophys Res Commun. 2025 Jun 7:776:152161.|Biochem Pharmacol. 2024 Dec;230 (Pt 2) :116593.|Biomacromolecules. 2025 Jun 9;26 (6) :3852-3867.|bioRxiv. 2024 May 10.|bioRxiv. 2025 February 13.|Cancer Immunol Res. 2022 Dec 2;10 (12) :1542-1558.|Cell Death Dis. 2021 Jun 7;12 (6) :582.|Cell Metab. 2023 Nov 7;35 (11) :1961-1975.e6.|Cell Metab. 2025 Jan 7;37 (1) :87-103.e10.|Cell Rep Med. 2025 Oct 21;6 (10) :102410.|Chemosphere. 2019 Jun:225:378-387.|Curr Microbiol. 2023 May 31;80 (7) :230.|Curr Res Food Sci. 2025 May 16:10:101084.|Emerg Microbes Infect. 2022 Dec;11 (1) :815-828.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Environ Health Perspect. 2022 Jun;130 (6) :67009.|Food Funct. 2025 Jul 14;16 (14) :5885-5899.|Front Microbiol. 2020 Jul 31:11:1720.|Future Microbiol. 2025 Oct 13:1-10.|Genome Biol. 2023 Apr 30;24 (1) :98.|Gut Microbes. 2023 Dec;15 (2) :2249143.|Heliyon. 2024 Jan 6;10 (1) :e24239.|Infect Drug Resist. 2021 Dec 16;14:5449-5456.|Int Immunopharmacol. 2025 May 21:159:114888.|Int J Biol Macromol. 2024 Sep 19:135835.|Int J Biol Macromol. 2025 Mar 19:142276.|Int J Med Microbiol. 2020 Jan;69 (1) :120-131.|Int J Med Sci. 2022 Apr 11;19 (4) :740-752.|iScience. 2022 Jan 5;25 (2) :103731.|iScience. 2023 Mar 11;26 (4) :106378.|iScience. 2023 Oct 7;26 (11) :108158.|iScience. 2025 May 13;28 (7) :112658.|iScience. 2025 May 27;28 (6) :112763.|J Agric Food Chem. 2024 Apr 10.|J Appl Microbiol. 2024 Jan 2;135 (1) :lxae001.|J Cell Physiol. 2022 Mar;237 (3) :1845-1856.|J Neuroinflammation. 2025 Nov 4;22 (1) :259.|J Pharm Anal. 2023 Oct;13 (10) :1153-1167.|Life Metab. 2025 Oct 8.|Life Sci. 2020 Nov 15;261:118473.|Microb Biotechnol. 2021 Nov;14 (6) :2538-2551.|Microbiol Spectr. 2022 Apr 27;10 (2) :e0054121.|Microbiol Spectr. 2025 Oct 15:e0122125.|Microbiol Spectr. 2025 Oct 23:e0157625.|Microbiologyopen. 2025 Oct;14 (5) :e70062.|Mol Immunol. 2022 Sep:149:94-106.|Mol Pharm. 2022 Nov 7;19 (11) :4320-4332.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398 (4) :3681-3695.|Neural Regen Res. 2024 Sep 1;19 (9) :2081-2088.|Pharmacol Res. 2024 May 21:205:107229.|Phytomedicine. 2024 Nov 28:136:156297.|Res Sq. 2024 Oct 02.|Research Square Preprint. 2020 Jun.|Research Square Preprint. 2024 Nov 13.|Transl Res. 2023 Mar:253:16-30.|Virulence. 2024 Dec;15 (1) :2367659.|Virulence. 2024 Dec;15 (1) :2415952.|Cancer Cell. 2025 Sep 25:S1535-6108 (25) 00394-0.|Cell Rep. 2025 Feb 28;44 (3) :115356.|Chem Eng J. 2024 Apr 15, 486 150125.|Front Aging Neurosci. 2022 Jul 28;14:858130.|Front Pharmacol. 2025 Dec 1:16:1657343.|NPJ Biofilms Microbiomes. 2024 Oct 28;10 (1) :111.|PLoS One. 2025 Jul 10;20 (7) :e0328167.|PLoS Pathog. 2025 Jun 9;21 (6) :e1013179.|Pol J Microbiol. 2023 Jun 14;72 (2) :199-208.|Redox Biol. 2023 Nov:67:102929.|Small. 2022 Mar;18 (10) :e2107137.